Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Scott Biller sold 2,146 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $67.23, for a total transaction of $144,275.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Scott Biller also recently made the following trade(s):

  • On Monday, September 11th, Scott Biller sold 15,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $65.00, for a total transaction of $975,000.00.
  • On Friday, September 1st, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $61.99, for a total transaction of $133,030.54.
  • On Wednesday, August 2nd, Scott Biller sold 23,146 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $59.60, for a total transaction of $1,379,501.60.
  • On Friday, July 7th, Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $55.00, for a total transaction of $118,030.00.

Agios Pharmaceuticals, Inc. (AGIO) traded up 0.26% during mid-day trading on Thursday, reaching $70.43. 197,591 shares of the company were exchanged. Agios Pharmaceuticals, Inc. has a 12 month low of $39.24 and a 12 month high of $71.40. The company’s market cap is $3.41 billion. The stock’s 50-day moving average is $63.02 and its 200-day moving average is $55.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by ($0.21). The firm had revenue of $11.30 million for the quarter, compared to analyst estimates of $10.68 million. Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The firm’s quarterly revenue was up 62.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.47) earnings per share. Equities analysts expect that Agios Pharmaceuticals, Inc. will post ($7.08) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Agios Pharmaceuticals, Inc. (AGIO) Insider Scott Biller Sells 2,146 Shares of Stock” was first published by Marea Informative and is the property of of Marea Informative. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at http://www.mareainformativa.com/agios-pharmaceuticals-inc-agio-insider-scott-biller-sells-2146-shares-of-stock/117904/.

Several institutional investors have recently made changes to their positions in AGIO. Bank of Montreal Can lifted its holdings in Agios Pharmaceuticals by 11.7% in the 1st quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 216 shares during the last quarter. Blue Sky Asset Management LLC acquired a new stake in Agios Pharmaceuticals in the 1st quarter worth approximately $129,000. QS Investors LLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter worth approximately $144,000. Russell Investments Group Ltd. lifted its holdings in Agios Pharmaceuticals by 163.9% in the 1st quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock worth $149,000 after purchasing an additional 1,583 shares during the last quarter. Finally, Cubist Systematic Strategies LLC lifted its holdings in Agios Pharmaceuticals by 1,041.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 3,123 shares during the last quarter. Institutional investors and hedge funds own 94.40% of the company’s stock.

AGIO has been the topic of several recent analyst reports. Canaccord Genuity set a $90.00 price objective on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 8th. SunTrust Banks, Inc. reiterated a “buy” rating and set a $80.00 price objective (up from $68.00) on shares of Agios Pharmaceuticals in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. set a $75.00 price objective on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, June 11th. Cann reiterated a “buy” rating and set a $75.00 price objective on shares of Agios Pharmaceuticals in a report on Sunday, June 11th. Finally, BidaskClub upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 13th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Agios Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $75.20.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.